These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3835 related articles for article (PubMed ID: 27959700)

  • 1. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    Mok TS; Wu Y-L; Ahn M-J; Garassino MC; Kim HR; Ramalingam SS; Shepherd FA; He Y; Akamatsu H; Theelen WS; Lee CK; Sebastian M; Templeton A; Mann H; Marotti M; Ghiorghiu S; Papadimitrakopoulou VA;
    N Engl J Med; 2017 Feb; 376(7):629-640. PubMed ID: 27959700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
    Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
    Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
    John T; Akamatsu H; Delmonte A; Su WC; Lee JS; Chang GC; Huang X; Jenkins S; Wu YL
    Lung Cancer; 2018 Dec; 126():133-138. PubMed ID: 30527177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib with or without Chemotherapy in
    Planchard D; Jänne PA; Cheng Y; Yang JC; Yanagitani N; Kim SW; Sugawara S; Yu Y; Fan Y; Geater SL; Laktionov K; Lee CK; Valdiviezo N; Ahmed S; Maurel JM; Andrasina I; Goldman J; Ghiorghiu D; Rukazenkov Y; Todd A; Kobayashi K;
    N Engl J Med; 2023 Nov; 389(21):1935-1948. PubMed ID: 37937763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK
    J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
    Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
    Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
    Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok TSK; Yang JC; Hoyle C
    Clin Drug Investig; 2018 Apr; 38(4):319-331. PubMed ID: 29247383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
    Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
    Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
    Nie K; Zhang Z; Zhang C; Geng C; Zhang L; Xu X; Liu S; Wang S; Zhuang X; Lan K; Ji Y
    Lung Cancer; 2018 Jul; 121():5-11. PubMed ID: 29858027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
    Yang JC; Ahn MJ; Kim DW; Ramalingam SS; Sequist LV; Su WC; Kim SW; Kim JH; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin CC; Mann H; Cantarini M; Ghiorghiu S; Jänne PA
    J Clin Oncol; 2017 Apr; 35(12):1288-1296. PubMed ID: 28221867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Goss G; Tsai CM; Shepherd FA; Bazhenova L; Lee JS; Chang GC; Crino L; Satouchi M; Chu Q; Hida T; Han JY; Juan O; Dunphy F; Nishio M; Kang JH; Majem M; Mann H; Cantarini M; Ghiorghiu S; Mitsudomi T
    Lancet Oncol; 2016 Dec; 17(12):1643-1652. PubMed ID: 27751847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
    Saw SPL; Low YF; Lai GGY; Chan LL; Wong WKY; Tsui G; Chen OH; Seet AOL; Tan WC; Tan AC; Chan JWK; Teh YL; Tan WL; Ng QS; Ang MK; Kanesvaran R; Lim DWT; Tan DSW; Mok TSK; Li MSC
    Lung Cancer; 2024 Jul; 193():107856. PubMed ID: 38889498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
    Kiura K; Yoh K; Katakami N; Nogami N; Kasahara K; Takahashi T; Okamoto I; Cantarini M; Hodge R; Uchida H
    Cancer Sci; 2018 Apr; 109(4):1177-1184. PubMed ID: 29363250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 192.